363 related articles for article (PubMed ID: 28589339)
1. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
Okanoue T; Ebise H; Kai T; Mizuno M; Shima T; Ichihara J; Aoki M
J Gastroenterol; 2018 Jan; 53(1):129-139. PubMed ID: 28589339
[TBL] [Abstract][Full Text] [Related]
2. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease.
Sumida Y; Yoneda M; Hyogo H; Yamaguchi K; Ono M; Fujii H; Eguchi Y; Suzuki Y; Imai S; Kanemasa K; Fujita K; Chayama K; Yasui K; Saibara T; Kawada N; Fujimoto K; Kohgo Y; Okanoue T;
J Gastroenterol; 2011 Feb; 46(2):257-68. PubMed ID: 20842510
[TBL] [Abstract][Full Text] [Related]
3. New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan.
Kawamura Y; Ikeda K; Arase Y; Sorin Y; Fukushima T; Kunimoto H; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Kumada H
Hepatol Int; 2015 Apr; 9(2):269-77. PubMed ID: 25788193
[TBL] [Abstract][Full Text] [Related]
4. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
5. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.
Tada T; Kumada T; Toyoda H; Saibara T; Ono M; Kage M
Biomarkers; 2018; 23(4):328-334. PubMed ID: 29308929
[TBL] [Abstract][Full Text] [Related]
6. MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.
Chuah KH; Wan Yusoff WNI; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK
Liver Int; 2019 Jul; 39(7):1315-1324. PubMed ID: 30825254
[TBL] [Abstract][Full Text] [Related]
7. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage.
Yoneda M; Mawatari H; Fujita K; Yonemitsu K; Kato S; Takahashi H; Kirikoshi H; Inamori M; Nozaki Y; Abe Y; Kubota K; Saito S; Iwasaki T; Terauchi Y; Togo S; Maeyama S; Nakajima A
J Gastroenterol; 2007 May; 42(5):375-81. PubMed ID: 17530362
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
9. Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease.
Ogawa Y; Honda Y; Kessoku T; Tomeno W; Imajo K; Yoneda M; Kawanaka M; Kirikoshi H; Ono M; Taguri M; Saito S; Yamanaka T; Wada K; Nakajima A
J Gastroenterol Hepatol; 2018 Oct; 33(10):1795-1803. PubMed ID: 29633352
[TBL] [Abstract][Full Text] [Related]
10. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
Kozumi K; Kodama T; Murai H; Sakane S; Govaere O; Cockell S; Motooka D; Kakita N; Yamada Y; Kondo Y; Tahata Y; Yamada R; Hikita H; Sakamori R; Kamada Y; Daly AK; Anstee QM; Tatsumi T; Morii E; Takehara T
Hepatology; 2021 Nov; 74(5):2452-2466. PubMed ID: 34105780
[TBL] [Abstract][Full Text] [Related]
12. Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms.
Lykiardopoulos B; Hagström H; Fredrikson M; Ignatova S; Stål P; Hultcrantz R; Ekstedt M; Kechagias S
PLoS One; 2016; 11(12):e0167776. PubMed ID: 27936091
[TBL] [Abstract][Full Text] [Related]
13. Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
Kobayashi N; Kumada T; Toyoda H; Tada T; Ito T; Kage M; Okanoue T; Kudo M
Dig Dis; 2017; 35(6):521-530. PubMed ID: 29040984
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study.
Itoh Y; Seko Y; Shima T; Nakajima T; Mizuno K; Kawamura Y; Akuta N; Ito K; Kawanaka M; Hiramatsu A; Sakamoto M; Harada K; Goto Y; Nakayama T; Kumada H; Okanoue T
Hepatol Res; 2018 Dec; 48(13):1099-1107. PubMed ID: 29974624
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
Pennisi G; Enea M; Falco V; Aithal GP; Palaniyappan N; Yilmaz Y; Boursier J; Cassinotto C; de Lédinghen V; Chan WK; Mahadeva S; Eddowes P; Newsome P; Karlas T; Wiegand J; Wong VW; Schattenberg JM; Labenz C; Kim W; Lee MS; Lupsor-Platon M; Cobbold JFL; Fan JG; Shen F; Staufer K; Trauner M; Stauber R; Nakajima A; Yoneda M; Bugianesi E; Younes R; Gaia S; Zheng MH; Cammà C; Anstee QM; Mózes FE; Pavlides M; Petta S
Hepatology; 2023 Jul; 78(1):195-211. PubMed ID: 36924031
[TBL] [Abstract][Full Text] [Related]
16. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels.
Gawrieh S; Wilson LA; Cummings OW; Clark JM; Loomba R; Hameed B; Abdelmalek MF; Dasarathy S; Neuschwander-Tetri BA; Kowdley K; Kleiner D; Doo E; Tonascia J; Sanyal A; Chalasani N;
Am J Gastroenterol; 2019 Oct; 114(10):1626-1635. PubMed ID: 31517638
[TBL] [Abstract][Full Text] [Related]
17. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
[TBL] [Abstract][Full Text] [Related]
18. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining.
Yoshimura K; Okanoue T; Ebise H; Iwasaki T; Mizuno M; Shima T; Ichihara J; Yamazaki K
Hepatology; 2016 Feb; 63(2):462-73. PubMed ID: 26390046
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
